References
- Agrawal A, Murphy RF, Agrawal DK (2007). DNA methylation in breast and colorectal cancers. Mod Pathol, 20, 711-21 https://doi.org/10.1038/modpathol.3800822
- Bandaru S, Ponnala D, Lakkaraju C, et al (2014). Identification of high affinity non-peptidic small molecule inhibitors of mdm2-p53 interactions through structure-based virtual screening strategies. Asian Pac J Cancer Prev, 16, 3759-65.
- Bandaru S, Tiwari G, Akka J, et al (2015). Identification of high affinity bioactive salbutamol conformer directed against mutated (thr164ile) beta 2 adrenergic receptor. Curr Top Med Chem, 15, 50-6. https://doi.org/10.2174/1568026615666150112113040
- Blair LP, Yan Q (2012). Epigenetic mechanisms in commonly occurring cancers. DNA Cell Biol, 31, 49-61.
- Bolden JE, Peart MJ, Johnstone RW (2006). Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Disc, 5, 769-84 https://doi.org/10.1038/nrd2133
- Cai J, Wei H, Hong KH, et al (2015). Discovery, bioactivity and docking simulation of Vorinostat analogues containing 1, 2, 4-oxadiazole moiety as potent histone deacetylase inhibitors and antitumor agents. Bioorg Med Chem, 23, 3457-71. https://doi.org/10.1016/j.bmc.2015.04.028
- Cheng F, Li W, Zhou Y, et al (2012). Admet SAR: a comprehensive source and free tool for assessment of chemical ADMET properties. J Chem Inf Model, 52, 3099-105. https://doi.org/10.1021/ci300367a
- Clayton AL, Hazzalin CA, Mahadevan LC (2006). Enhanced histone acetylation and transcription: a dynamic perspective. Mol Cell, 23, 289-96. https://doi.org/10.1016/j.molcel.2006.06.017
- De Ruijter AJ, van Gennip AH, Caron HN, et al (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370, 737-49 https://doi.org/10.1042/bj20021321
- Dokmanovic M, Clarke C, Marks PA (2007). Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res, 5, 981-9 https://doi.org/10.1158/1541-7786.MCR-07-0324
- Dokmanovic M, Marks PA (2005). Prospects: histone deacetylase inhibitors. J Cell Biochem, 96, 293-304 https://doi.org/10.1002/jcb.20532
- Fouladi M (2006). Histone deacetylase inhibitors in cancer therapy. Cancer Invest, 24, 521-7 https://doi.org/10.1080/07357900600814979
- Fraga MF, Ballestar E, Villar-Garea A, et al (2005). Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet, 37, 391-400 https://doi.org/10.1038/ng1531
- Glozak MA, Seto E (2007). Histone deacetylases and cancer. Oncogene, 26, 5420-32 https://doi.org/10.1038/sj.onc.1210610
- Grant S, Easley C, Kirkpatrick P (2007). Vorinostat. Nat Rev Drug Discov, 6, 21-2. https://doi.org/10.1038/nrd2227
- Johnstone RW (2002). Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 1, 287-99. https://doi.org/10.1038/nrd772
- Kelly TK, De Carvalho DD, Jones PA (2010). Epigenetic modifications as therapeutic targets. Nat Biotechnol, 28, 1069-78. https://doi.org/10.1038/nbt.1678
- Kelotra S, Jain M, Kelotra A, et al (2014). An in silico Appraisal to Identify High Affinity Anti-Apoptotic Synthetic Tetrapeptide Inhibitors Targeting the Mammalian Caspase 3 Enzyme. Asian Pac J Cancer Prev, 15, 10137-42.
- Lafon-Hughes L, Di Tomaso MV, Mendez-Acuna L, et al (2008). Chromatin-remodelling mechanisms in cancer. Mutat Res, 658, 191-214 https://doi.org/10.1016/j.mrrev.2008.01.008
- Lauffer, Benjamin EL, Robert Mintzer, et al (2013). Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. J Biol Chem, 288, 26926-43. https://doi.org/10.1074/jbc.M113.490706
- Magnaghi-Jaulin L, Eot-Houllier G, Fulcrand G, et al (2007). Histone deacetylase inhibitors induce premature sister chromatid separation and override the mitotic spindle assembly checkpoint. Cancer Res, 67, 6360-7 https://doi.org/10.1158/0008-5472.CAN-06-3012
- Mariadason JM (2008). HDACs and HDAC inhibitors in colon cancer. Epigenetics, 3, 28-37. https://doi.org/10.4161/epi.3.1.5736
- Nelder JA, Mead R (1965). A simplex method for function minimization. Comput J, 7, 308-13. https://doi.org/10.1093/comjnl/7.4.308
- Piekarz RL, Sackett DL, Bates SE (2007). Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy. Cancer J, 13, 30-9 https://doi.org/10.1097/PPO.0b013e31803c73cc
- Shen L, Issa JP (2002). Epigenetics in colorectal cancer. Curr Opin Gastroenterol, 18, 68-73 https://doi.org/10.1097/00001574-200201000-00012
- Stevens FE, Beamish H, Warrener R, et al (2008). Histone deacetylase inhibitors induce mitotic slippage. Oncogene, 27, 1345-54 https://doi.org/10.1038/sj.onc.1210779
- Thomsen R, Christensen MH (2006). MolDock: a new technique for high-accuracy molecular docking. J Med Chem, 49, 3315-21. https://doi.org/10.1021/jm051197e
- Xu WS, Perez G, Ngo L, et al (2005). Induction of polyploidy by histone deacetylase inhibitor: a pathway for antitumor effects. Cancer Res, 65, 7832-9 https://doi.org/10.1158/0008-5472.CAN-04-4608
- Yang JM, Chen CC (2004). Gemdock: A generic evolutionary method for molecular docking. Proteins, 55, 288-304. https://doi.org/10.1002/prot.20035